Patents by Inventor Orrin Devinsky

Orrin Devinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20200069608
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20200000741
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: September 13, 2019
    Publication date: January 2, 2020
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20190091171
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: November 21, 2018
    Publication date: March 28, 2019
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • IDENTIFICATION OF EPILEPSY PATIENTS AT INCREASED RISK FROM SUDDEN UNEXPECTED DEATH IN EPILEPSY
    Publication number: 20180355432
    Abstract: Provided is a method for predicting an individual to be at risk of developing sudden unexpected death in epilepsy (SUDEP) comprising determining the presence or absence of mutations in the genes ITPR1, GABRR2, JUP, SSTR5, F2, KCNMB1, CNTNAP2, GRM8, GNAI2, TUBA3D, GRIK1, GRIK5 and DPP6, or determining if the expression of certain cardiac arrhythmia genes or gamma-aminobutyric acid/glutamate metabolism genes are increased or decreased.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 13, 2018
    Inventors: Matija SNUDERL, Kasthuri KANNAN, Daniel FRIEDMAN, Orrin DEVINSKY
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20180338931
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: April 9, 2018
    Publication date: November 29, 2018
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 10137095
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 27, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 10111840
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 30, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 10092525
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 9, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 9956185
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 9956186
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 9956183
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 9956184
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: May 1, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 9949937
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 24, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20170266126
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 3, 2017
    Publication date: September 21, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING
    Publication number: 20170239193
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy the disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: October 14, 2015
    Publication date: August 24, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY
    Publication number: 20170231923
    Abstract: The present disclosure relatesto the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: October 14, 2015
    Publication date: August 17, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20170181982
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20170173044
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20170172939
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Use of Cannabinoids in the Treatment of Epilepsy
    Publication number: 20170172940
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky